DNA Sequencing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The DNA Sequencing Market is Segmented by Product Type (Instruments, Consumables, and Other Product Types), Sequencing Type (Sanger Sequencing, Next Generation Sequencing, and Other Sequencing Types), Application (Diagnostics, Personalized Medicine, and Other Applications), End User (Hospitals and Healthcare Organizations, Academics and Research Institutions, Pharmaceutical and Biotechnology Companies, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

DNA Sequencing Market Overview
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 18.61 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The DNA sequencing market was valued at approximately USD 8,712.10 million in 2020, and it is expected to reach USD 24,257.75 million by 2026, registering a CAGR of 18.61% during the forecast period, 2021-2026. The certain factors that are driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery, and growing investments in R&D.

The COVID-19 pandemic has been having a positive impact on the market studied, as this is increasing the demand for DNA sequencing technology in the development of therapeutics and diagnostics. For instance, in August 2020, Helix COVID-19 NGS test was authorized by FDA under an Emergency Use Authorization (EUA) for use only by Helix Laboratory; it is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19. Hence, owing to the increasing DNA sequencing-based research and development activities in the development of diagnostic tools or effective therapeutics for COVID-19, the market is likely to continue its significant growth rate during the forecast period.

DNA sequencing has its applications in diagnostics, personalized medicine, biomarkers, forensics, reproductive health, and other applications. The DNA sequencing technology holds great potential in clinical research and development of cancer diagnostics and therapeutics. Recently, the next-generation sequencing (NGS) technology has demonstrated its capacity as a high-throughput and affordable approach in the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test. According to a research article by Hong-Yan Liu et al., published in Scientific Reports Journal 2019, it has been estimated that 80% of rare diseases are genetic in origin, and thus, genome sequencing-based diagnosis offers a promising alternative for rare-disease management, which is expected to have a positive impact on the market studied. Therefore, the increasing application of DNA sequencing in clinical diagnosis and drug discovery is expected to drive the market growth over the forecast period.

The technological advancements in sequencing, from 2D sequencing in the 1970s to DNA sequencing, have come a long way. In recent years, platforms such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos have provided unique prospects for high-throughput functional genomic research. Moreover, biologists and informatics experts have been focusing on the development of better genomes, one made possible by newer sequencing technologies, novel methods for locating sequences on chromosomes, and improved software for DNA sequencing.

In addition, the next-generation sequencing (NGS) technology has been gaining popularity as a routine clinical diagnostic test, particularly with the pandemic of COVID-19 infection, which shows a positive impact on the market. Thus, the increasing advancements in DNA sequencing technologies are contributing to the growth of the market studied.

Scope of the Report

As per the scope of the report, DNA sequencing is the procedure of determining or identifying the sequence of nucleotides within a DNA molecule. It enables scientists to sequence genes and genomes. After identifying and analyzing the genes from sequence information, scientists can get information about mutations, which cause disease, thus providing significant medical information. The DNA sequencing market is segmented by product type (instruments, consumables, and other product types), sequencing type (Sanger sequencing, next generation sequencing, and other sequencing types), application (diagnostics, personalized medicine, and other applications), end user (hospitals and healthcare organizations, academics and research institutions, pharmaceutical and biotechnology companies, and other end users), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Product Type
Instruments
Consumables (Kits and Reagents)
Other Product Types
By Sequencing Type
Sanger Sequencing
Next Generation Sequencing
Other Sequencing Types
By Application
Diagnostics
Personalized Medicine
Other Applications
By End User
Hospitals and Healthcare Organizations
Academics and Research Institutions
Pharmaceutical and Biotechnology Companies
Other End Users
Geography
North America
United States (By Product Type, Sequencing Type, Application, and End User)
Canada (By Product Type, Sequencing Type, Application, and End User)
Mexico (By Product Type, Sequencing Type, Application, and End User)
Europe
Germany (By Product Type, Sequencing Type, Application, and End User)
United Kingdom (By Product Type, Sequencing Type, Application, and End User)
France (By Product Type, Sequencing Type, Application, and End User)
Italy (By Product Type, Sequencing Type, Application, and End User)
Spain (By Product Type, Sequencing Type, Application, and End User)
Rest of Europe (By Product Type, Sequencing Type, Application, and End User)
Asia-Pacific
China (By Product Type, Sequencing Type, Application, and End User)
Japan (By Product Type, Sequencing Type, Application, and End User)
India (By Product Type, Sequencing Type, Application, and End User)
Australia (By Product Type, Sequencing Type, Application, and End User)
South Korea (By Product Type, Sequencing Type, Application, and End User)
Rest of Asia-Pacific (By Product Type, Sequencing Type, Application, and End User)
Middle-East and Africa
GCC (By Product Type, Sequencing Type, Application, and End User)
South Africa (By Product Type, Sequencing Type, Application, and End User)
Rest of Middle-East and Africa (By Product Type, Sequencing Type, Application, and End User)
South America
Brazil (By Product Type, Sequencing Type, Application, and End User)
Argentina (By Product Type, Sequencing Type, Application, and End User)
Rest of South America (By Product Type, Sequencing Type, Application, and End User)

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Next Generation Sequencing Segment is Expected to Dominate the Market During the Forecasted Period

The next generation sequencing segment is being driven by factors such as the increasing applications of NGS, speed, cost, accuracy, efficient replacement of traditional technologies, and drug discovery applications demanding NGS technology. The advantage of this technology is that it is significantly cheaper, quicker, and needs significantly lesser DNA, which helps in the overall growth of the segment.

With the COVID-19 pandemic, there has been an increase in the adoption of next-generation sequencing technology in the diagnostics of infections, owing to its high efficiency and accuracy. In June 2020, the FDA issued an emergency use authorization to Ilumina Inc. for the product COVIDSeq Test, the first COVID-19 diagnostic test utilizing next-generation sequence technology. The advantage of using a next-generation sequencing test is that it can generate information about the genomic sequence of the virus present in a sample along with detecting the presence of the virus in the sample. This genomic information can be used for research purposes too, thus supporting the growth of the market.

There are various technological advancements in the field of medicine that are growing at a rapid pace and have led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the growth of the segment.

Along with the advantages and increasing demand for this technology, the launches and advancements are huge boosters to the segment growth. For instance, Thermo Fisher Scientific launched its Ion Torrent Genexus System in November 2019, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. Hence, owing to the above-mentioned factors, the segment is expected to grow during the forecast period.

DNA Sequencing Market Latest Trends

North America Dominates the Market and is Expected to do the Same in the Forecast Period

North America dominated the market studied owing to the increase in funding and support activities by the government and non-government entities, especially in the United States. The increasing adoption of advanced technologies and favorable support from the government and related policies are the primary driving factors for DNA sequencing in the country.

With the rising COVID-19 pandemic, there is a positive impact on the market growth. For instance, in April 2020, Genome Canada launched the Canadian COVID Genomics Network (CanCOGeN), a newly formed initiative backed by funding of USD 40 million. Led by Genome Canada, in partnership with the six regional Genome Centers, national and provincial public health labs, genome sequencing centers through CGEn, hospitals, universities, and the private sector, CanCOGeN will scale up genomics-based COVID-19 research in Canada.

There are also various government bodies, like the US-based National Human Genome Research Institute (NHGRI), that have been supporting research related to human genome sequencing while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on ethical, legal, and social implications of genome research.

In December 2020, Illumina Inc. and Harvard Pilgrim Health Care announced a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January 2021. The program will leverage WGS to support faster diagnoses of genetic diseases in children, potentially eliminating the long, costly diagnostic process experienced by many families, with the goal of improving patient outcomes.

In November 2019, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, which is the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. ​ Hence, owing to these factors, the DNA sequencing market is expected to be one of the largest in the future.​

DNA Sequencing Market Growth Rate By Region

Competitive Landscape

The DNA sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc., Merck KGaA, Pacific Biosciences of California Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc., among others, hold substantial shares in the DNA sequencing market. These companies are making efforts to address the rising consumer demand as well as making significant investments in production, distribution, and total quality management for the expansion of their portfolios.

Recent Developments

In February 2020, MGI, part of the global genomics leader BGI Group, announced the commercial availability of its sequencing instruments and reagent kits in the United States.

In May 2020, the Swedish biotechnology company CARTANA launched an expanded range of In Situ Sequencing kits for high throughput single-cell gene expression mapping.

In October 2020, Bio-Rad Laboratories Inc. announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit, a novel approach to RNA-Seq library preparation.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Technological Advancements in DNA Sequencing

      2. 4.2.2 Increasing Application in Clinical Diagnosis and Drug Discovery

      3. 4.2.3 Growing Investments in R&D

    3. 4.3 Market Restraints

      1. 4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals

      2. 4.3.2 Legal and Ethical Issues

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Instruments

      2. 5.1.2 Consumables (Kits and Reagents)

      3. 5.1.3 Other Product Types

    2. 5.2 By Sequencing Type

      1. 5.2.1 Sanger Sequencing

      2. 5.2.2 Next Generation Sequencing

      3. 5.2.3 Other Sequencing Types

    3. 5.3 By Application

      1. 5.3.1 Diagnostics

      2. 5.3.2 Personalized Medicine

      3. 5.3.3 Other Applications

    4. 5.4 By End User

      1. 5.4.1 Hospitals and Healthcare Organizations

      2. 5.4.2 Academics and Research Institutions

      3. 5.4.3 Pharmaceutical and Biotechnology Companies

      4. 5.4.4 Other End Users

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States (By Product Type, Sequencing Type, Application, and End User)

        2. 5.5.1.2 Canada (By Product Type, Sequencing Type, Application, and End User)

        3. 5.5.1.3 Mexico (By Product Type, Sequencing Type, Application, and End User)

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany (By Product Type, Sequencing Type, Application, and End User)

        2. 5.5.2.2 United Kingdom (By Product Type, Sequencing Type, Application, and End User)

        3. 5.5.2.3 France (By Product Type, Sequencing Type, Application, and End User)

        4. 5.5.2.4 Italy (By Product Type, Sequencing Type, Application, and End User)

        5. 5.5.2.5 Spain (By Product Type, Sequencing Type, Application, and End User)

        6. 5.5.2.6 Rest of Europe (By Product Type, Sequencing Type, Application, and End User)

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China (By Product Type, Sequencing Type, Application, and End User)

        2. 5.5.3.2 Japan (By Product Type, Sequencing Type, Application, and End User)

        3. 5.5.3.3 India (By Product Type, Sequencing Type, Application, and End User)

        4. 5.5.3.4 Australia (By Product Type, Sequencing Type, Application, and End User)

        5. 5.5.3.5 South Korea (By Product Type, Sequencing Type, Application, and End User)

        6. 5.5.3.6 Rest of Asia-Pacific (By Product Type, Sequencing Type, Application, and End User)

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC (By Product Type, Sequencing Type, Application, and End User)

        2. 5.5.4.2 South Africa (By Product Type, Sequencing Type, Application, and End User)

        3. 5.5.4.3 Rest of Middle-East and Africa (By Product Type, Sequencing Type, Application, and End User)

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil (By Product Type, Sequencing Type, Application, and End User)

        2. 5.5.5.2 Argentina (By Product Type, Sequencing Type, Application, and End User)

        3. 5.5.5.3 Rest of South America (By Product Type, Sequencing Type, Application, and End User)

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Agilent Technologies Inc.

      2. 6.1.2 Bio-Rad Laboratories Inc.

      3. 6.1.3 Danaher Corporation (Integrated DNA Technologies Inc.)

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Illumina Inc.

      6. 6.1.6 Merck KGaA

      7. 6.1.7 PerkinElmer Inc.

      8. 6.1.8 Thermo Fisher Scientific Inc.

      9. 6.1.9 QIAGEN

      10. 6.1.10 Macrogen Inc.

      11. 6.1.11 Myriad Genetics Inc.

      12. 6.1.12 Intrexon Bioinformatics Germany GmbH

      13. 6.1.13 Eurofins Scientific

      14. 6.1.14 Hamilton Thorne Biosciences

      15. 6.1.15 Pacific Biosciences of California Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global DNA Sequencing Market market is studied from 2018 - 2026.

The Global DNA Sequencing Market is growing at a CAGR of 18.61% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck KGaA, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd. are the major companies operating in Global DNA Sequencing Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!